# WNK2 (W-14): sc-51252



The Power to Question

### **BACKGROUND**

The protein kinase superfamily contains over a thousand proteins in 57 subfamilies that all share a catalytic core of 250-300 amino acids organized in 2 domains. WNK, for "with no lysine (K)", kinases are serine-threonine protein kinases that contain a cysteine residue in place of a lysine residue in a family of proteins that traditionally contain a lysine following a short string of hydrophobic residues. WNK kinases contain a lysine upstream of the traditional position, within a glycine string. This lysine functions as an anchor and orients ATP through interactions with the  $\alpha$  and  $\beta$  phosphoryl groups. The catalytic domains of WNK2, WNK3 and WNK4 are 95% homologous to WNK1. The human WNK1 gene encodes a 2,382 amino acid protein that is primarily expressed in heart, kidney, muscle and distal nephron. The human WNK3 gene encodes a protein that is primarily expressed in brain; the human WNK4 gene encodes a 1,243 amino acid protein that is expressed in kidney. Aberrant function of WNK kinases and their associated signaling pathways are implicated in hypertension, increased renal salt reabsorption and impaired K+ and H+ excretion.

## **REFERENCES**

- Xu, B., English, J.M., Wilsbacher, J.L., Stippec, S., Goldsmith, E.J. and Cobb, M.H. 2000. WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. J. Biol. Chem. 275: 16795-16801.
- 2. Verissimo, F. and Jordan, P. 2001. WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. Oncogene 20: 5562-5569.
- Wilson, F.H., Disse-Nicodeme, S., Choate, K.A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D.V., Lipkin, G.W., et al. 2001. Human hypertension caused by mutations in WNK kinases. Science 293: 1107-1112.
- Xu, B.E., Min, X., Stippec, S., Lee, B.H., Goldsmith, E.J. and Cobb, M.H. 2002. Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J. Biol. Chem. 277: 48456-48462.
- Hollenberg, N.K. 2002. Human hypertension caused by mutations in WNK kinases. Curr. Hypertens. Rep. 4: 267.
- Nakamichi, N., Murakami-Kojima, M., Sato, E., Kishi, Y., Yamashino, T. and Mizuno, T. 2002. Compilation and characterization of a novel WNK family of protein kinases in *Arabiodpsis thaliana* with reference to circadian rhythms. Biosci. Biotechnol. Biochem. 66: 2429-2436.
- Yang, C.L., Angell, J., Mitchell, R. and Ellison, D.H. 2003. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J. Clin. Invest. 111: 1039-1045.
- Tobin, M.D., Raleigh, S.M., Newhouse, S., Braund, P., Bodycote, C., Ogleby, J., Cross, D., Gracey, J., Hayes, S., Smith, T., et al. 2005.
  Association of WNK1 gene polymorphisms and haplotypes with ambulatory blood pressure in the general population. Circulation 112: 3423-3429.

# **CHROMOSOMAL LOCATION**

Genetic locus: WNK2 (human) mapping to 9q22.31.

### **SOURCE**

WNK2 (W-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of WNK2 of human origin.

## **PRODUCT**

Each vial contains 200  $\mu g$  IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-51252 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

#### **APPLICATIONS**

WNK2 (W-14) is recommended for detection of WNK2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

WNK2 (W-14) is also recommended for detection of WNK2 in additional species, including equine and canine.

Suitable for use as control antibody for WNK2 siRNA (h): sc-61803, WNK2 shRNA Plasmid (h): sc-61803-SH and WNK2 shRNA (h) Lentiviral Particles: sc-61803-V.

Molecular Weight of WNK2: 243 kDa.

### **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

#### **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.



Try **WNK2 (46.21): sc-100452**, our highly recommended monoclonal alternative to WNK2 (W-14).

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com